



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|-----------------|-------------|----------------------|---------------------|------------------|
|-----------------|-------------|----------------------|---------------------|------------------|

10/662,678

09/15/2003

John P. Troup

8493-US

1877

74476

7590

11/24/2010

Nestle HealthCare Nutrition

12 Vreeland Road, 2nd Floor, Box 697

Florham Park, NJ 07932

EXAMINER

HA, JULIE

ART UNIT

PAPER NUMBER

1654

NOTIFICATION DATE

DELIVERY MODE

11/24/2010

ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

patentdepartment@rd.nestle.com

athena.pretory@rd.nestle.com

| | | | |
|------------------------------|--------------------------------------|-------------------------------------|--|
| Office Action Summary | Application No. 10/662,678 | Applicant(s) TROUP ET AL. | |
| | Examiner JULIE HA | Art Unit 1654 | |

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 13 September 2010.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-4, 6-14 and 16-28 is/are pending in the application.
- 4a) Of the above claim(s) 6, 12 and 18-22 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-4, 7-11, 13, 14, 16, 17 and 23-28 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Amendment after Non-final office action filed on September 13, 2010 is acknowledged. Claims 1-4, 6-14 and 16-28 are pending in this application. Claims 6, 12 and 18-22 remain withdrawn from further consideration, as being drawn to nonelected inventions and species. Claims 1-4, 7-11, 13-14, 16-17 and 23-28 are examined on the merits in this office action. After further review, a non final office action follows below.

1. This application contains claims 6, 12 and 18-22 drawn to an invention nonelected with traverse in the reply filed on October 4, 2007. A complete reply to the final rejection must include cancellation of nonelected claims or other appropriate action (37 CFR 1.144) See MPEP § 821.01.

Withdrawn Rejection

2. Rejection of claims 1, 23-25 under 35 U.S.C. 102(b) as being anticipated by Heyland et al (US Patent No. 4,544,568) is hereby withdrawn in view of Applicant's amendment. However, a new 103 rejection follows due to Applicant's amendment.

Revised and Maintained Rejection

35 U.S.C. 103

3. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the

Art Unit: 1654

invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148

USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

For the purpose of this invention, the level of ordinary skill in the art is deemed to be at least that level of skill demonstrated by the patents in the relevant art. *Joy Technologies Inc. V. Quigg*, 14 USPQ2d 1432 (DC DC 1990). One of ordinary skill in the art is held in accountable not only for specific teachings of references, but also for inferences which those skilled in the art may reasonably be expected to draw. *In re Hoeschele*, 160 USPQ 809, 811 (CCPA 1969). In addition, one of ordinary skill in the art is motivated by economics to depart from the prior art to reduce costs consistent with desired product properties. *In re Clinton*, 188 USPQ 365, 367 (CCPA 1976); *In re Thompson*, 192 USPQ 275, 277 (CCPA 1976).

4. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

5. (Revised due to Applicant's amendment) Claims 1-4, 7-11, 13-14, 16-17 and 23-28 remain rejected under 35 U.S.C. 103(a) as unpatentable over Abbruzzese et al (US Patent No. 6,077,828) as evidenced by Roberts (US Patent No. 4,112,123), in view of

Art Unit: 1654

Hageman et al (US Patent No. 6,420,342) and Salvati et al (US Patent No. 6,953,679) and Vickery (US Patent No. 6,203,820).

6. Abbruzzese et al teach nutritional compositions for the prevention of cachexia and anorexia. The reference teaches a composition comprising effective amounts of ω -3 fatty acids, such as alpha-linolenic acid, stearidonic acid, eicosapentanenoic acid, docosapentaenoic acid, docosahexanoic acid or mixtures thereof; of branched-chain amino acids valine, leucine, isoleucine or mixtures thereof; with or without reduced levels of tryptophan and 5-hydroxytryptophan; and of antioxidant system selected from the group consisting of beta-carotene, vitamin C, vitamin E, selenium or mixtures thereof (see abstract). The reference teaches a liquid nutritional composition comprising (a) at least 1000 mg per liter of ω -3 fatty acids, wherein the weight ratio of ω -6 fatty acids to ω -3 fatty acids is from about 0.1 to about 1.0; (b) at least 50 grams per liter of a source of amino nitrogen, wherein 15 to 50% by weight of the amino-nitrogen is branched-chain amino acids, and wherein tryptophan is present in an amount less than about 5.0% by weight of the total amino -nitrogen, and (c) at least 1 gram per liter of an antioxidant system comprising beta-carotene, vitamin C, vitamin E and selenium (see claim 1). The reference teaches that the total amount of branched-chain amino acids ("BCAA") useful in the present invention is about 15-50 g/100 g protein (i.e. percent), preferably about 15-25 g/100 g. Thus, an 8 oz container of the nutritional composition would contain up to about 8 g BCAAs per 16 grams of total protein. The daily delivery of BCAAs is about 5-26 g (see column 9, lines 26-31). The reference teaches the branched-chain amino acids valine, leucine, isoleucine or mixtures thereof (see

Art Unit: 1654

abstract). Therefore, since there is 9.08 g and total of 19.75 g of BCAA, $9.08/19.75$ is about 46% of the leucine in the BCAA. Since the reference teaches that the total amount of BCAA useful in the present invention is about 15-50 g/100 g protein, and there is 46% of leucine in the BCAA composition, this implies that there is about 23% of leucine. Additionally, the reference teaches that the nutritional compositions comprises branched-chain amino acids, valine, leucine, isoleucine or mixtures of thereof.

Furthermore, the reference teaches that the liquid nutritional composition comprises per liter (a) at least 0.45 gm (450 mg) of ω -3 fatty acids, (b) at least 50 grams of a source of amino-nitrogen wherein 15-50% by weight of the amino-nitrogen is branched-chain amino acids and wherein tryptophan is present in an amount less than about 5.0% of the total amino-nitrogen, and (c) at least 1 gram of an antioxidant (see column 4, lines 20-36). Therefore, if there was 46% of leucine present, and 46% of 50 gram is 23 grams of leucine present in the composition, this implies that there is about 46% of leucine present in the composition.

The reference further teaches that the composition comprises essential amino acids, such as lysine, isoleucine, methionine, phenylalanine, threonine, tryptophan, valine or histidine, and teaches the amino acid profile of a nutritional composition (see Table 4). Since there is at least about 36 g of essential and/or conditionally essential amino acids per serving and about 15-50 g of BCAA per 100 g of protein, meeting the limitation of claims 14 and 16. Furthermore, since the reference teaches that there is at least 50 grams of a source of amino-nitrogen wherein 15-50% by weight of the amino nitrogen is BCAA, and Table 4 indicates that 9.08 gram of leucine is present, according

Art Unit: 1654

to the calculation above, this equals about 46% of BCAA. Thus, if 50% by weight of the amino nitrogen is BCAA, there is at least 25 grams of BCAA present. And if about 46% of BCAA is leucine, this implies that there is about 11.5 g of leucine present, meeting the limitation of claim 26. The reference teaches 2.78 g of methionine in 100 g of protein, meeting the limitation of at least about 0.5% to about 5% of methionine of claim 7. The reference teaches that the nutritional composition comprises vitamin E (tocopherol (all natural form or d1-alpha-tocopherol acetate) (see Table 6), meeting the limitation of claim 11. The reference teaches that the EPA is in the amount of 1.09 g and DHA is in the amount of 0.46 g (see Table 3), meeting the limitation of claims 8-10. The reference further teaches that for treatment of ulcerative colitis, compositions include a protein source that can be intact or hydrolyzed proteins of high biological value (see column 3, lines 1-5) and teaches 75% whey protein concentrate as one of the ingredients (see table 7). Furthermore, since the reference teaches a whey protein concentrate, this protein would inherently comprise essential and conditionally essential amino acid profiled, thus meeting the limitation of range from about 0.60 to about 0.90 amino acids.

As evidenced by Roberts (US Patent No. 4,112,123), per 100 g of whey protein, there is 13.0 g of leucine (see Table 1). Since there is at least 9.08 g of leucine to 13.0 g of leucine in 100 g of whey protein, this would meet the limitation of ratio of 1:3 to 3:1. Furthermore, the reference teaches that for example, the daily nutritional management of liver cancer includes administration of 2 to 4 containers of 8 ounces servings (237 mL) of the nutritional composition providing a daily amount of (i) combined EPA and

Art Unit: 1654

DHA in the range of 3 to 6 g (preferred dosage 3 g), (ii) BCAA in the range of 5 to 25 g (preferred dosage about 10-15 g), (iii) vitamin C in the range of 125 to 500 mg (preferred about 300 mg), (iv) vitamin E (tocopherol) in the range of 50 to 250 IU (preferred 150 IU), (v) beta-carotene in the range of 1250 to 3250 μg (preferred 2500 μg), (vi) selenium in the range of 40 to 60 μg (preferred about 45 μg). The reference teaches that for cancer cachexia and anorexia, the effect of nutritional intervention are monitored at monthly intervals as known in the art, and depending on the results obtained, the therapeutic regimen is developed to maintain and/or boost the weight gain by the patient (see column 15, lines 44-65, Example III). The mass equivalents of 1 IU for vitamin E is 0.667 mg d-alpha-tocopherol, or of 1 mg of d1-alpha-tocopherol acetate (definition of IU from medicinenet.com). Therefore, 50 to 250 IU would equal to 33.55 mg to 167.75 mg of tocopherol, meeting the limitation of claim 13.

The difference between the reference and the instant claims is that the reference does not teach at least 30% by weight of leucine based on the weight of intact protein, valine in an amount of about 8% to about 10% by weight of total amino acids, a kit comprising a first composition and a second composition comprising an anti-cancer drug, wherein said anticancer drug is 5-fluorouracil, mitomycin-C, adriamycin, chloroethyl nitrosureas or methotrexate, and that the methionine in free and/or salt form is in an amount of at least about 5% to about 7% by weight on the weight of total amino acids.

7. However, Hageman et al teach a nutritional, pharmaceutical or dietetic preparation can be manufacture in dry form, as bar, as powder, as tablet, and cookie or

Art Unit: 1654

as cereal (see column 5, lines 60-63). The reference teaches for products for sportsmen the following mixtures of amino acids appeared to be especially beneficial for muscle growth, when consumed in an amount of more than 2 and preferably more than 4 g per daily dose: 3-10 wt% histidine, 5-15% isoleucine, 10-23% % leucine, 10-23% lysine, 5-15% methionine, 5-15 wt % phenylalanine, and 5-15 wt % threonine (see column 6, lines 59-67 and column 7, line 1). Furthermore, the reference teaches that when proteins are included in the nutritional preparations, the amount that is included depends on the application (see column 6, lines 39-41) and the proteins are proteins of dairy, vegetable or animal origin, such as skimmed milk powder, whey powder, egg white powder, potato protein, soy protein, etc., or hydrolysates, or mixtures thereof (see column 6, lines 27-32). The reference teaches that when proteins are included in the nutritional preparation, the amount that is included depends on the application of the product. In complete formula typically an amount of 5-120 g per daily dose...for young infants the amount will be in the range 5-15 g per daily dose...in complete enteral nutrition for feeding surgery patients, typically 50-120 g per daily dose...In supplement typically 0-60 g protein per daily dose will be included (see column 6, lines 39-50). In regards to claim 25, the claim is drawn to "a composition consisting essentially of..." In regards to claim 27, the claim is drawn to "a kit comprising: a first composition consisting essentially of..." Applicant has not defined what encompasses "consisting essentially of" in the specification. In fact the instant specification does not define the phrase "consisting essentially of". The MPEP states the following: "The transitional phrase 'consisting essentially of' limits the scope of a claim to the specified materials or

Art Unit: 1654

steps "and those that do not materially affect the basic and novel characteristic(s)" of the claimed invention. A 'consisting essentially of' claim occupies the middle ground between closed claims that are written in a consisting of' format and fully open claims that are drafted in a comprising' format...For the purposes of searching for and applying prior art under 35 U.S.C. 102 and 103, absent a clear indication in the specification or claims of what the basic and novel characteristics actually are, "consisting essentially of" will be construed as equivalent to 'comprising'" (see MPEP 2105). Therefore, claims 25 and 28 have been treated as "a composition comprising..." the same claim language as original claim 3.

8. Furthermore, Salvati et al teach a fused cyclic compound and the use of the fused cyclic compound with a nutritional supplements in combination with whey protein or casein, amino acids (such as leucine, branched amino acid and hydroxymethylbutyrate), triglycerides, vitamins (e.g., A, B6, B12, folate, C, D, and E), minerals, etc (see column 45, lines 48-56). Furthermore, the reference teaches anti-proliferative agents for use in combination with the compounds such as adriamycin (see column 45, lines 41-43) and anti-cancer agents, such as methotrexate, 5-fluorouracil (see column 46, lines 64-67). The reference teaches a kit comprising a first container (such as a vial) containing a pharmaceutical formulation comprising a compound, a second container (such as a vial) containing a pharmaceutical formulation comprising one or more agents to be used in combination with the compound of the invention (see 47, lines 55-64).

Art Unit: 1654

9. Additionally, Vickery et al teach a composition for enhancing protein anabolism, and nutritional composition comprising L-arginine, L-cysteine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-threonine, L-tryptophan, L-tyrosine, and L-valine (see abstract and claim 1). Vickery teaches that L-leucine is useful in for lowering blood sugar, stimulating protein synthesis in muscle and wound healing of skin and bone (see column 3, lines 51-54). Vickery teaches that L-valine aids in wound healing, muscle growth and liver diseases. L-valine is present in the composition in an amount of from about 7% to about 10% by weight, from about 8% to about 9% by weight (see column 2, lines 12-30 and column 4, lines 48-53, and claims 18 and 20-21).

10. Therefore, it would have been obvious for one of ordinary skill in the art to combine the teachings of Abbruzzese et al, Hageman et al and Salvati et al and Vickery reference to produce a kit comprising the anti-cancer agent with the nutritional composition, since all of the prior art teach nutritional composition. Salvati et al teach a kit comprising fused cyclic compound, nutritional supplement comprising leucine, whey and protein and any anti-cancer agent and Hageman et al and Abbruzzese et al and Vickery teach a nutritional composition comprising different amounts of amino acids. One of ordinary skill in the art would be motivated to combine, since Salvati et al teaches such a composition/kit. Furthermore, the composition taught in Abbruzzese, Hageman, and Salvati and Vickery can be used for the same purpose, for administering nutritional composition for such patients as cancer patients for enhancing protein anabolism and muscle enhancement. As evidenced by the instant specification, the

Art Unit: 1654

compositions of the instant application are for the promotion of muscle protein synthesis and control of tumor-induced weight loss in patients that are, for example, suffering from cancer cachexia (see abstract). Furthermore, one of ordinary skill in the art would have been motivated to optimize the concentrations of the leucine and methionine and valine, since "it is the normal desire of scientist or artisans to improve upon what is already generally known provides the motivation to determine where in a disclosed set of percentage ranges is optimum combination of percentages". The MPEP states: Generally, differences in concentration or temperature will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration or temperature is critical. "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." *In re Aller*, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955) (Claimed process which was performed at a temperature between 40°C and 80°C and an acid concentration between 25% and 70% was held to be prima facie obvious over a reference process which differed from the claims only in that the reference process was performed at a temperature of 100°C and an acid concentration of 10%.); see also *Peterson*, 315 F.3d at 1330, 65 USPQ2d at 1382 ("The normal desire of scientists or artisans to improve upon what is already generally known provides the motivation to determine where in a disclosed set of percentage ranges is the optimum combination of percentages."); *In re Hoeschele*, 406 F.2d 1403, 160 USPQ 809 (CCPA 1969) (Claimed elastomeric polyurethanes which fell within the broad scope of the references were held to be unpatentable thereover because, among other reasons,

Art Unit: 1654

there was no evidence of the criticality of the claimed ranges of molecular weight or molar proportions.). For more recent cases applying this principle, see *Merck & Co. Inc. v. Biocraft Laboratories Inc.*, 874 F.2d 804, 10 USPQ2d 1843 (Fed. Cir.), cert. denied, 493 U.S. 975 (1989); *In re Kulling*, 897 F.2d 1147, 14 USPQ2d 1056 (Fed. Cir. 1990); and *In re Geisler*, 116 F.3d 1465, 43 USPQ2d 1362 (Fed. Cir. 1997). Furthermore, Abbruzzese patent '828 teaches that the effect of nutritional intervention on cancer cachexia and anorexia are monitored as known in the art, and depending on the results obtained, the therapeutic regimen is developed to maintain and /or boost weight gain by the patient, with the ultimate goal of achieving tumor regression and complete eradication of cancer cells (see column 15, lines 57-64). Therefore, there is a reasonable expectation of success to optimize the concentrations of the essential amino acid/ leucine/ methionine, since it is "the normal desire of scientists or artisans to improve upon what is already generally known provides the motivation to determine where in a disclosed set of percentage ranges is the optimum combination of percentages" and one of ordinary skill in the art would experiment with different concentrations to produce the optimal product. Due to the loss of appetite due to cancer treatment, and due to appetite suppression, nutrition is necessarily a part of treatment process for improving patient's everyday life. For the process of improving and treating cancer and loss of appetite due to cancer, a nutritional requirement would be optimized and adjusted accordingly by those skilled in the art. Abbruzzese teaches that the therapeutic regimen will be developed to maintain and/or boost weight gain, giving motivation to optimize the nutritional content. From the teachings of the references, it is

Art Unit: 1654

apparent that one of the ordinary skills in the art would have had a reasonable expectation of success in producing the claimed invention. Thus, the invention as a whole is *prima facie* obvious over the references, especially in the absence of evidence to the contrary. There is a reasonable expectation of success, since Salvati et al teach a kit that can comprise any agent, nutritional supplement for the treatment of cancer (prostate), and Hageman et al and Abbruzzese et al teach a nutritional supplement comprising essential amino acids that is useful in treating variety of diseases, including cancer, and Vickery teaches a nutritional composition comprising essential amino acid, including leucine, valine, isoleucine and methionine to enhance protein anabolism and enhancing muscle growth and protein synthesis in the muscle.

11. (Revised due to amendment to the claims) Claims 1-4, 7-11, 13-14, 16 and 23-26 are rejected under 35 U.S.C. 103(a) as being unpatentable over Abbruzzese et al (US Patent No. 6,077,828, filed with IDS) as evidenced by Roberts (US Patent No. 4,112,123), in view of Allen et al (US 2003/0119888 A1) and Phillips Bill (Sports Supplement Review, 1997, pp. 66-70) and Vickery (US Patent No. 6,203,820).

12. Abbruzzese et al teach nutritional compositions for the prevention of cachexia and anorexia. The reference teaches a composition comprising effective amounts of ω -3 fatty acids, such as alpha-linolenic acid, stearidonic acid, eicosapentanenoic acid, docosapentaenoic acid, docosahexanoic acid or mixtures thereof; of branched-chain amino acids valine, leucine, isoleucine or mixtures thereof; with or without reduced levels of tryptophan and 5-hydroxytryptophan; and of antioxidant system selected from

Art Unit: 1654

the group consisting of beta-carotene, vitamin C, vitamin E, selenium or mixtures thereof (see abstract). The reference teaches a liquid nutritional composition comprising (a) at least 1000 mg per liter of ω -3 fatty acids, wherein the weight ratio of ω -6 fatty acids to ω -3 fatty acids is from about 0.1 to about 1.0; (b) at least 50 grams per liter of a source of amino nitrogen, wherein 15 to 50% by weight of the amino-nitrogen is branched-chain amino acids, and wherein tryptophan is present in an amount less than about 5.0% by weight of the total amino -nitrogen, and (c) at least 1 gram per liter of an antioxidant system comprising beta-carotene, vitamin C, vitamin E and selenium (see claim 1). The reference teaches that the total amount of branched-chain amino acids ("BCAA") useful in the present invention is about 15-50 g/100 g protein (i.e. percent), preferably about 15-25 g/100 g. Thus, an 8 oz container of the nutritional composition would contain up to about 8 g BCAAs per 16 grams of total protein. The daily delivery of BCAAs is about 5-26 g (see column 9, lines 26-31). The reference teaches the branched-chain amino acids valine, leucine, isoleucine or mixtures thereof (see abstract). Therefore, since there is 9.08 g and total of 19.75 g of BCAA, $9.08/19.75$ is about 46% of the leucine in the BCAA. Since the reference teaches that the total amount of BCAA useful in the present invention is about 15-50 g/100 g protein, and there is 46% of leucine in the BCAA composition, this implies that there is at least about 23% of leucine. Additionally, the reference teaches that the nutritional compositions comprises branched-chain amino acids, valine, leucine, isoleucine or mixtures of thereof. As evidenced by Roberts (US Patent No. 4,112,123), per 100 g of whey protein,

Art Unit: 1654

there is 13.0 g of leucine (see Table 1). Since there is at least 9.08 g of leucine to 13.0 g of leucine in 100 g of whey protein, this would meet the limitation of ratio of 1:3 to 3:1.

Furthermore, the reference teaches that the liquid nutritional composition comprises per liter (a) at least 0.45 gm (450 mg) of ω -3 fatty acids, (b) at least 50 grams of a source of amino-nitrogen wherein 15-50% by weight of the amino-nitrogen is branched-chain amino acids and wherein tryptophan is present in an amount less than about 5.0% of the total amino-nitrogen, and (c) at least 1 gram of an antioxidant (see column 4, lines 20-36). Therefore, if there was 46% of leucine present, and 46% of 50 gram is 23 grams of leucine present in the composition, this implies that there is about 46% of leucine present in the composition.

The reference further teaches that the composition comprises essential amino acids, such as lysine, isoleucine, methionine, phenylalanine, threonine, tryptophan, valine or histidine, and teaches the amino acid profile of a nutritional composition (see Table 4). Since there is at least about 36 g of essential and/or conditionally essential amino acids per serving and about 15-50 g of BCAA per 100 g of protein, meeting the limitation of claims 14 and 16. Furthermore, since the reference teaches that there is at least 50 grams of a source of amino-nitrogen wherein 15-50% by weight of the amino nitrogen is BCAA, and Table 4 indicates that 9.08 gram of leucine is present, according to the calculation above, this equals about 46% of BCAA. Thus, if 50% by weight of the amino nitrogen is BCAA, there is at least 25 grams of BCAA present. And if about 46% of BCAA is leucine, this implies that there is about 11.5 g of leucine present, meeting the limitation of claim 26. The reference teaches 2.78 g of methionine in 100 g of

Art Unit: 1654

protein, meeting the limitation of at least about 0.5% to about 5% of methionine of claim 7.

The reference further teaches that the nutritional composition comprises vitamin E (tocopherol (all natural form or d1-alpha-tocopherol acetate) (see Table 6), meeting the limitation of claim 11. The reference teaches that the EPA is in the amount of 1.09 g and DHA is in the amount of 0.46 g (see Table 3), meeting the limitation of claims 8-10. The reference further teaches that for treatment of ulcerative colitis, compositions include a protein source that can be intact or hydrolyzed proteins of high biological value (see column 3, lines 1-5) and teaches 75% whey protein concentrate as one of the ingredients (see table 7). Furthermore, since the reference teaches a whey protein concentrate, this protein would inherently comprise essential and conditionally essential amino acid profiled, thus meeting the limitation of range from about 0.60 to about 0.90 amino acids. Furthermore, the reference teaches that for example, the daily nutritional management of liver cancer includes administration of 2 to 4 containers of 8 ounces servings (237 mL) of the nutritional composition providing a daily amount of (i) combined EPA and DHA in the range of 3 to 6 g (preferred dosage 3 g), (ii) BCAA in the range of 5 to 25 g (preferred dosage about 10-15 g), (iii) vitamin C in the range of 125 to 500 mg (preferred about 300 mg), (iv) vitamin E (tocopherol) in the range of 50 to 250 IU (preferred 150 IU), (v) beta-carotene in the range of 1250 to 3250 μg (preferred 2500 μg), (vi) selenium in the range of 40 to 60 μg (preferred about 45 μg). The reference teaches that for cancer cachexia and anorexia, the effect of nutritional intervention are monitored at monthly intervals as known in the art, and depending on the results

Art Unit: 1654

obtained, the therapeutic regimen is developed to maintain and/or boost the weight gain by the patient (see column 15, lines 44-65, Example III). The mass equivalents of 1 IU for vitamin E is 0.667 mg d-alpha-tocopherol, or of 1 mg of d1-alpha-tocopherol acetate (definition of IU from medicinenet.com). Therefore, 50 to 250 IU would equal to 33.55 mg to 167.75 mg of tocopherol, meeting the limitation of claim 13. The difference between the reference and the instant claims is that the reference does not teach at least 30% to about 95% by weight of leucine and about 8% to about 10% valine.

13. However, Allen teaches that maintaining muscle mass while minimizing the accumulation of fat has long been an issue of concern to athletes. Food and/or vitamin supplements, as well as pituitary growth hormone, are necessary for muscle growth. Such ergogenic aids, that is supplements which stimulate muscle growth, include the three amino acids, leucine, isoleucine and valine (see paragraph [0004]). Furthermore, Phillips (1997) teaches that beta-hydroxy beta-methylbutyrate (HMB) is a metabolite of the essential amino acid leucine (see p. 66, "What is HMB?"). Phillips teaches that HMB up-regulate the ability to build muscle and burn fat, and may help decrease stress-induced muscle protein breakdown, and enhance increases in both muscle size and strength (see p. 66, "What do the scientific studies show?").

14. Additionally, Vickery et al teach a composition for enhancing protein anabolism, and nutritional composition comprising L-arginine, L-cysteine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-threonine, L-tryptophan, L-tyrosine, and L-valine (see abstract and claim 1). Vickery teaches that L-leucine is useful in for lowering blood sugar, stimulating protein synthesis in muscle and wound

Art Unit: 1654

healing of skin and bone (see column 3, lines 51-54). Vickery teaches that L-valine aids in wound healing, muscle growth and liver diseases. L-valine is present in the composition in an amount of from about 7% to about 10% by weight, from about 8% to about 9% by weight (see column 2, lines 12-30 and column 4, lines 48-53, and claims 18 and 20-21).

15. Therefore, it would have been obvious to one of ordinary skill in the art to combine the teachings and optimize the amount of leucine and valine in the composition to enhance the muscle performance. One of ordinary skill in the art would have been motivated to optimize the amount of leucine and valine in the composition, since Allen teaches that leucine, isoleucine and valine are three amino acids that stimulate muscle growth, Phillips teaches that leucine breaks down into HMB that build muscle, burn fat, and increases in both muscle size and strengths, and Vickery teaches that L-leucine is useful in for lowering blood sugar, stimulating protein synthesis in muscle and wound healing of skin and bone. Vickery teaches that L-valine aids in wound healing, muscle growth and liver diseases. L-valine is present in the composition in an amount of from about 7% to about 10% by weight, from about 8% to about 9% by weight. One would be motivated to give leucine to produce the down stream compound HMB and valine to aid in muscle growth. Again, Leu, Ile and Val are well known to be used for stimulating muscle growth. The MPEP states that "Similarly, a prima facie case of obviousness exists where the claimed ranges and prior art ranges do not overlap but are close enough that one skilled in the art would have expected them to have the same properties. *Titanium Metals Corp of America v. Banner*, 778 F.2d 775, 227 USPQ 773

Art Unit: 1654

(Fed. Cir. 1985).” See MPEP 2144.05. The artisan would have expected Leu to behave the same at 25 or 30 or 35. Applicant’s own example 4 shows clearly that Leu does not improve muscle building. The amount of protein synthesis and protein breakdown for both 25% leucine and 35% leucine was about the same for both leucine concentrations (see Table 4 of instant specification). Therefore, the differing concentrations of leucine would function the same. It appears that the additional components are important to the reduction of breakdown (see Table 4 of instant specification).

Furthermore, the MPEP further states: Generally, differences in concentration or temperature will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration or temperature is critical.

“[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation.” In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955) (Claimed process which was performed at a temperature between 40°C and 80°C and an acid concentration between 25% and 70% was held to be prima facie obvious over a reference process which differed from the claims only in that the reference process was performed at a temperature of 100°C and an acid concentration of 10%.); see also Peterson, 315 F.3d at 1330, 65 USPQ2d at 1382 (“The normal desire of scientists or artisans to improve upon what is already generally known provides the motivation to determine where in a disclosed set of percentage ranges is the optimum combination of percentages.”); In re Hoeschele, 406 F.2d 1403, 160 USPQ 809 (CCPA 1969) (Claimed elastomeric polyurethanes which fell within the broad scope of the references were held to be

Art Unit: 1654

unpatentable thereover because, among other reasons, there was no evidence of the criticality of the claimed ranges of molecular weight or molar proportions.). For more recent cases applying this principle, see *Merck & Co. Inc. v. Biocraft Laboratories Inc.*, 874 F.2d 804, 10 USPQ2d 1843 (Fed. Cir.), cert. denied, 493 U.S. 975 (1989); *In re Kulling*, 897 F.2d 1147, 14 USPQ2d 1056 (Fed. Cir. 1990); and *In re Geisler*, 116 F.3d 1465, 43 USPQ2d 1362 (Fed. Cir. 1997). Knowing that leucine, isoleucine and valine stimulate muscle growth, it would have been obvious to one of ordinary skill in the art to optimize the concentrations of leucine, isoleucine or valine to enhance the muscle growth. Furthermore, since leucine produces the down stream compound of HMB that is important in muscle growth and stimulation, it would have been obvious to optimize the concentration of leucine to produce the optimal composition. From the teachings of the references, it is apparent that one of the ordinary skills in the art would have had a reasonable expectation of success in producing the claimed invention.

Thus, the invention as a whole is *prima facie* obvious over the references, especially in the absence of evidence to the contrary.

Response to Applicant's Arguments

16. Applicant argues that "Applicant has surprisingly found that a formulation containing free essential amino acids as compared to a formulation containing free essential and non-essential amino acids or intact protein is optimal...In addition, Applicant has surprisingly and unexpectedly found that particularly useful compositions for promotion of muscle protein synthesis or controlling tumor-induced weight loss, such

Art Unit: 1654

as cachexia, e.g. cancer cachexia may be obtained by combining essential amino acids in free form and/or in salt form with intact protein." Applicant argues that "Abbruzzese, Roberts, Hageman, Salvati, Allen and Phillips fail to disclose or suggest compositions having leucine, valine in an amount of about 8% to about 10% by weight based on the weight of total amino acids, and at least one essential amino acid selected from histidine, and combinations thereof in free and/or salt form, wherein said leucine, in free and/or salt form are required." Applicant argues that "Hageman discloses products having the following mixture of amino acids as beneficial for muscle growth when consumes in an amount more than 2 and preferably more than 4 g per daily dose: 3-10 wt % histidine, 5-15 wt % isoleucine, 10-23% leucine, 10-23% lysine, 5-15 wt % methionine, 5-15 wt % phenylalanine, 5-15 wt % threonine." Applicant argues that "At no place in the disclosure does Salvati, Roberts, Allen and Phillips disclose or suggest compositions containing about 8% to about 10% of valine, as required, in part, by the present claims."

17. Applicant's arguments have been fully considered but have not been found persuasive. The instant claims are drawn to a composition. The claims are not drawn to method claims, and do not recite any intended use. The primary reference teaches all of the active components of instant claims. The claims only require that valine in an amount of about 8% to about 10% by weight based on the weight of total amino acids, and at least 30% to about 95% by weight of leucine be present based on the weight of total amino acids or weight of intact protein. The prior arts meet this limitation. As described in the body of the rejection, the reference teaches a liquid nutritional

Art Unit: 1654

composition comprising (a) at least 1000 mg per liter of ω -3 fatty acids, wherein the weight ratio of ω -6 fatty acids to ω -3 fatty acids is from about 0.1 to about 1.0; (b) at least 50 grams per liter of a source of amino nitrogen, wherein 15 to 50% by weight of the amino-nitrogen is branched-chain amino acids, and wherein tryptophan is present in an amount less than about 5.0% by weight of the total amino -nitrogen, and (c) at least 1 gram per liter of an antioxidant system comprising beta-carotene, vitamin C, vitamin E and selenium (see claim 1). The reference teaches that the total amount of branched-chain amino acids ("BCAA") useful in the present invention is about 15-50 g/100 g protein (i.e. percent), preferably about 15-25 g/100 g. The reference teaches that the daily delivery of BCAAs is about 5-26 g (see column 9, lines 26-31). The reference teaches the branched-chain amino acids valine, leucine, isoleucine or mixtures thereof (see abstract). Since there is 9.08 g of leucine and total of 19.75 g of BCAA, 9.08/19.75 is about 46% of the leucine in the BCAA. Since the reference teaches that the total amount of BCAA useful in the present invention is about 15-50 g/100 g protein, and there is 46% of leucine in the BCAA composition, this implies that there is about 23% of leucine.

Hageman et al teach a nutritional, pharmaceutical or dietetic preparation can be manufacture in dry form, as bar, as powder, as tablet, and cookie or as cereal (see column 5, lines 60-63). The reference teaches for products for sportsmen the following mixtures of amino acids appeared to be especially beneficial for muscle growth, when consumed in an amount of more than 2 and preferably more than 4 g per daily dose: 3-10 wt% histidine, 5-15% isoleucine, 10-23% % leucine, 10-23% lysine, 5-15%

Art Unit: 1654

methionine, 5-15 wt % phenylalanine, and 5-15 wt % threonine (see column 6, lines 59-67 and column 7, line 1). Furthermore, Salvati et al teach a fused cyclic compound and the use of the fused cyclic compound with a nutritional supplements in combination with whey protein or casein, amino acids (such as leucine, branched amino acid and hydroxymethylbutyrate), triglycerides, vitamins (e.g., A, B6, B12, folate, C, D, and E), minerals, etc (see column 45, lines 48-56). Furthermore, the reference teaches anti-proliferative agents for use in combination with the compounds such as adriamycin (see column 45, lines 41-43) and anti-cancer agents, such as methotrexate, 5-fluorouracil (see column 46, lines 64-67). The reference teaches a kit comprising a first container (such as a vial) containing a pharmaceutical formulation comprising a compound, a second container (such as a vial) containing a pharmaceutical formulation comprising one or more agents to be used in combination with the compound of the invention (see 47, lines 55-64). Allen and Phillips teach the importance of leucine, isoleucine and valine in stimulating muscle growth. Vickery teaches that L-leucine is useful in for lowering blood sugar, stimulating protein synthesis in muscle and wound healing of skin and bone. Vickery teaches that L-valine aids in wound healing, muscle growth and liver diseases. L-valine is present in the composition in an amount of from about 7% to about 10% by weight, from about 8% to about 9% by weight.

Therefore, it would have been obvious to one of ordinary skill in the art to combine the teachings because all references teach nutritional compositions comprising differing amounts of protein and essential amino acids (such as leucine) for the same purpose (muscle enhancement). Salvati reference teaches combining antiproliferative

Art Unit: 1654

agents for use in combination with the compounds and a kit containing the pharmaceutical formulation. Furthermore, the composition taught in Abbruzzese, Hageman, and Salvati can be used for the same purpose, for administering nutritional composition for such patients as cancer patients. Vickery reference teaches a nutritional composition and composition for enhancing protein anabolism. It would have been obvious to one of ordinary skill in the art to optimize the different amino acid concentration, especially leucine, since it is well known in the art that leucine, isoleucine and valine play an important role in muscle enhancement. The instant claims are drawn to a composition, and intended use is not recited. As evidenced by the instant specification, the compositions of the instant application are for the promotion of muscle protein synthesis and control of tumor-induced weight loss in patients that are, for example, suffering from cancer cachexia (see abstract). Due to the loss of appetite due to cancer treatment, and due to appetite suppression, nutrition is necessarily a part of treatment process for improving patient's everyday life. For the process of improving and treating cancer and loss of appetite due to cancer, a nutritional requirement would be optimized and adjusted accordingly by those skilled in the art. Abbruzzese teaches that the therapeutic regimen will be developed to maintain and/or boost weight gain, giving motivation to optimize the nutritional content. From the teachings of the references, it is apparent that one of the ordinary skills in the art would have had a reasonable expectation of success in producing the claimed invention. Thus, the invention as a whole is *prima facie* obvious over the references, especially in the absence of evidence to the contrary. There is a reasonable expectation of success,

Art Unit: 1654

since Salvati et al teach a kit that can comprise any agent, nutritional supplement for the treatment of cancer (prostate), and Hageman et al and Abbruzzese et al teach a nutritional supplement comprising essential amino acids that is useful in treating variety of diseases, including cancer. Both Allen and Phillips references were utilized to show the important role leucine plays in muscle enhancement. Vickery reference teaches the importance of L-valine and the composition comprising about 7 to about 10% leucine along with other amino acids.

In response to Applicant's argument regarding "surprising and unexpected benefits of the claimed composition having optimal amount of leucine and essential amino acids," Applicant has not compared the results of the instant components to the components of prior arts. The specification discloses that protein synthesis in muscle in Leu (25%) was 6.8 ± 1.1 ; Leu(35%) was 6.9 ± 0.6 ; Leucine alone was 6.6 ± 0.7 . Protein breakdown in Leu (25%) was 8.1 ± 1.2 ; Leu (35%) was 8.0 ± 0.4 ; Leucine alone was 9.2 ± 0.5 (see Table 4). There is not much difference between Leu (25%) and Leu (35%) and Leu alone for protein synthesis. There is not much difference between Leu (25%) and Leu (35%) for protein breakdown.

It is known in the art that that supplements which stimulate muscle growth, include the three amino acids, leucine, isoleucine and valine (see paragraph [0004] in Allen reference). Furthermore, Phillips (1997) teaches that beta-hydroxy beta-methylbutyrate (HMB) is a metabolite of the essential amino acid leucine (see p. 66, "What is HMB?"). Phillips teaches that HMB up-regulate the ability to build muscle and burn fat, and may help decrease stress-induced muscle protein breakdown, and

Art Unit: 1654

enhance increases in both muscle size and strength (see p. 66, "What do the scientific studies show?"). Therefore, one of ordinary skill in the art would have been motivated to optimize the concentration of different amino acids, specifically leucine, isoleucine and valine to stimulate muscle growth, to arrive at the optimal composition for the treatment of muscle enhancement for cancer patients.

New Rejection

35 U.S.C. 103

18. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

For the purpose of this invention, the level of ordinary skill in the art is deemed to be at least that level of skill demonstrated by the patents in the relevant art. *Joy Technologies Inc. V. Quigg*, 14 USPQ2d 1432 (DC DC 1990). One of ordinary skill in the art is held in accountable not only for specific teachings of references, but also for inferences which those skilled in the art may reasonably be expected to draw. *In re Hoeschele*, 160 USPQ 809, 811 (CCPA 1969). In addition, one of ordinary skill in the art is motivated

Art Unit: 1654

by economics to depart from the prior art to reduce costs consistent with desired product properties. In re Clinton, 188 USPQ 365, 367 (CCPA 1976); In re Thompson, 192 USPQ 275, 277 (CCPA 1976).

19. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

20. Claims 1, 23-25 are rejected under 35 U.S.C. 103(a) as being unpatentable over Heyland et al (US Patent No. 4,544,568) in view of Vickery (US Patent No. 6,203,820).

21. Heyland et al teach a composition comprising a 16 kg of technical leucine and 15 kg of whey powder (see column 5, lines 34-36). The reference teaches that technical leucine comprises a dry matter content of 99.6% and containing 65% of pure leucine, 13% of Cl⁻, 18% of isoleucine and 2% of valine, the remainder consisting primarily of ash and phenylalanine (see column 5, lines 24-28). The reference teaches a composition comprising 150 g technical leucine, and 180 g whey powder (see Examples 2 and 3). This implies that per 150 g of technical leucine, there is 97.5 g of leucine, 27 g of isoleucine, 3 g of valine and about 3 g of phenylalanine. Therefore, 97.5 g leucine / 180 g whey protein gives 54.2% leucine. The difference between the reference and the instant claims is that the reference does not teach about 8% to about 10% valine.

Art Unit: 1654

22. However, Vickery et al teach a composition for enhancing protein anabolism, and nutritional composition comprising L-arginine, L-cysteine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-threonine, L-tryptophan, L-tyrosine, and L-valine (see abstract and claim 1). Vickery teaches that L-leucine is useful in for lowering blood sugar, stimulating protein synthesis in muscle and wound healing of skin and bone (see column 3, lines 51-54). Vickery teaches that L-valine aids in wound healing, muscle growth and liver diseases. L-valine is present in the composition in an amount of from about 7% to about 10% by weight, from about 8% to about 9% by weight (see column 2, lines 12-30 and column 4, lines 48-53, and claims 18 and 20-21).

23. Therefore, it would have been obvious to one of ordinary skill in the art to combine the teachings of the prior arts because all references teach nutritional compositions comprising differing amounts of protein and essential amino acids (such as leucine) for the same purpose (muscle enhancement). One of ordinary skill in the art would be motivated to optimize the amounts of valine and isoleucine, since Vickery teaches that L-valine aids in wound healing, muscle growth and L-leucine is important in lowering blood sugar, stimulating protein synthesis in muscle and wound healing of skin and bond. Leu, Ile and Val are well known to be used for stimulating muscle growth. Vickery teaches about 7% to about 10% of leucine along with other amino acid compositions.

Furthermore, the MPEP further states: Generally, differences in concentration or temperature will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration or temperature is critical.

Art Unit: 1654

“[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation.” In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955) (Claimed process which was performed at a temperature between 40°C and 80°C and an acid concentration between 25% and 70% was held to be prima facie obvious over a reference process which differed from the claims only in that the reference process was performed at a temperature of 100°C and an acid concentration of 10%.); see also Peterson, 315 F.3d at 1330, 65 USPQ2d at 1382 (“*The normal desire of scientists or artisans to improve upon what is already generally known provides the motivation to determine where in a disclosed set of percentage ranges is the optimum combination of percentages.*”); In re Hoeschele, 406 F.2d 1403, 160 USPQ 809 (CCPA 1969) (Claimed elastomeric polyurethanes which fell within the broad scope of the references were held to be unpatentable thereover because, among other reasons, there was no evidence of the criticality of the claimed ranges of molecular weight or molar proportions.). For more recent cases applying this principle, see Merck & Co. Inc. v. Biocraft Laboratories Inc., 874 F.2d 804, 10 USPQ2d 1843 (Fed. Cir.), cert. denied, 493 U.S. 975 (1989); In re Kulling, 897 F.2d 1147, 14 USPQ2d 1056 (Fed. Cir. 1990); and In re Geisler, 116 F.3d 1465, 43 USPQ2d 1362 (Fed. Cir. 1997). Knowing that leucine, isoleucine and valine stimulate muscle growth, it would have been obvious to one of ordinary skill in the art to optimize the concentrations of leucine, isoleucine or valine to enhance the muscle growth. From the teachings of the references, it is apparent that one of the ordinary

Art Unit: 1654

skills in the art would have had a reasonable expectation of success in producing the claimed invention.

Thus, the invention as a whole is *prima facie* obvious over the references, especially in the absence of evidence to the contrary.

Conclusion

24. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). No claim is allowed.

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the date of this final action.

Art Unit: 1654

Any inquiry concerning this communication or earlier communications from the examiner should be directed to JULIE HA whose telephone number is (571)272-5982.

The examiner can normally be reached on Mon-Thurs, 5:30 AM to 4:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecilia Tsang can be reached on 571-272-0562. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Julie Ha/
Primary Examiner, Art Unit 1654